Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Search

Page Path
HOME > Search
1 "Eun-Jung Yim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Article
Complications
Severe Hypoglycemia and Cardiovascular or All-Cause Mortality in Patients with Type 2 Diabetes
Seon-Ah Cha, Jae-Seung Yun, Tae-Seok Lim, Seawon Hwang, Eun-Jung Yim, Ki-Ho Song, Ki-Dong Yoo, Yong-Moon Park, Yu-Bae Ahn, Seung-Hyun Ko
Diabetes Metab J. 2016;40(3):202-210.   Published online April 5, 2016
DOI: https://doi.org/10.4093/dmj.2016.40.3.202
  • 4,480 View
  • 60 Download
  • 49 Web of Science
  • 57 Crossref
AbstractAbstract PDFPubReader   
Background

We investigated the association between severe hypoglycemia (SH) and the risk of cardiovascular (CV) or all-cause mortality in patients with type 2 diabetes.

Methods

The study included 1,260 patients aged 25 to 75 years with type 2 diabetes from the Vincent Type 2 Diabetes Resgistry (VDR), who consecutively enrolled (n=1,260) from January 2000 to December 2010 and were followed up until May 2015 with a median follow-up time of 10.4 years. Primary outcomes were death from any cause or CV death. We investigated the association between the CV or all-cause mortality and various covariates using Cox proportional hazards regression analysis.

Results

Among the 906 participants (71.9%) who completed follow-up, 85 patients (9.4%) had at least one episode of SH, and 86 patients (9.5%) died (9.1 per 1,000 patient-years). Patients who had died were older, had a longer duration of diabetes and hypertension, received more insulin, and had more diabetic microvascular complications at baseline, as compared with surviving patients. The experience of SH was significantly associated with an increased risk of all-cause mortality (hazard ratio [HR], 2.64; 95% confidence interval [CI], 1.39 to 5.02; P=0.003) and CV mortality (HR, 6.34; 95% CI, 2.02 to 19.87; P=0.002) after adjusting for sex, age, diabetic duration, hypertension, mean glycosylated hemoglobin levels, diabetic nephropathy, lipid profiles, and insulin use.

Conclusion

We found a strong association between SH and increased risk of all-cause and CV mortality in patients with type 2 diabetes.

Citations

Citations to this article as recorded by  
  • The prognostic value of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in patients with diabetes or prediabetes: insights from NHANES 2005–2018
    Lei Ding, Hongda Zhang, Cong Dai, Aikai Zhang, Fengyuan Yu, Lijie Mi, Yingjie Qi, Min Tang
    Cardiovascular Diabetology.2024;[Epub]     CrossRef
  • Navigating the future of diabetes: innovative nomogram models for predicting all-cause mortality risk in diabetic nephropathy
    Sensen Wu, Hui Wang, Dikang Pan, Julong Guo, Fan Zhang, Yachan Ning, Yongquan Gu, Lianrui Guo
    BMC Nephrology.2024;[Epub]     CrossRef
  • Association of hypoglycaemia with the risks of arrhythmia and mortality in individuals with diabetes - a systematic review and meta-analysis
    Gangfeng Li, Shuping Zhong, Xingmu Wang, Fuyuan Zhuge
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Diabetes mellitus und Straßenverkehr – ein Positionspapier der Österreichischen Diabetesgesellschaft (Update 2023)
    Heidemarie Abrahamian, Birgit Salamon, Angelika Lahnsteiner, Christian Schelkshorn, Alexander Bräuer, Lars Stechemesser, Gerd Köhler, Martin Clodi
    Wiener klinische Wochenschrift.2023; 135(S1): 319.     CrossRef
  • Validation of the hypoglycemia awareness questionnaire to assess hypoglycemia awareness in patients with type 2 diabetes treated with insulin
    Diana Cristina Henao-Carrillo, Fabio Alexander Sierra-Matamoros, Ana Julia Carrillo Algarra, Julieth Patricia García-Lugo, Sandra Milena Hernández-Zambrano
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2023; 17(12): 102917.     CrossRef
  • Basal insulin analogues in people with diabetes and chronic kidney disease
    David León‐Jiménez, José Pablo Miramontes‐González, Laura Márquez‐López, Francisco Astudillo‐Martín, Luis M. Beltrán‐Romero, Fernando Moreno‐Obregón, Javier Escalada‐San Martín
    Diabetic Medicine.2022;[Epub]     CrossRef
  • Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study
    Eugene Han, Kyung-do Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Seung-Hyun Ko, Yong-ho Lee
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(5): e1976.     CrossRef
  • Validación transcultural del HypoA-Q para medir conciencia de hipoglucemia en pacientes diabéticos
    Ana Julia Carrillo-Algarra, Sandra Milena Hernandez-Zambrano, Fabio Alexander Sierra-Matamoros, Diana Cristina Henao-Carrillo, Ana María Gómez-Medina, Daniel Esteban Hurtado-Barrera
    Revista Ciencia y Cuidado.2022; 19(1): 42.     CrossRef
  • Validity of the diagnosis of diabetic microvascular complications in Korean national health insurance claim data
    Hyung Jun Kim, Moo-Seok Park, Jee-Eun Kim, Tae-Jin Song
    Annals of Clinical Neurophysiology.2022; 24(1): 7.     CrossRef
  • Severe hypoglycemia as a risk factor for cardiovascular outcomes in patients with type 2 diabetes: is it preventable?
    Seung-Hyun Ko
    Cardiovascular Prevention and Pharmacotherapy.2022; 4(3): 106.     CrossRef
  • Evaluation of a Clinical Platform to Promote Chronic Disease Management
    Laura Greene, Nila Sathe, John A. House, Laura L. Schott, Stella Safo
    Population Health Management.2021; 24(4): 470.     CrossRef
  • Severe hypoglycemia as a preventable risk factor for cardiovascular disease in patients with type 2 diabetes mellitus
    Soo-Yeon Choi, Seung-Hyun Ko
    The Korean Journal of Internal Medicine.2021; 36(2): 263.     CrossRef
  • Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents
    Katharina Mattishent, Yoon K. Loke
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Epidemiology and outcomes from severe hypoglycemia in Kuwait: a prospective cohort study
    Dalal Al Hasan, Ameen Yaseen, Mohammad Al Roudan, Lee Wallis
    BMC Emergency Medicine.2021;[Epub]     CrossRef
  • The incidence of hypoglycemia and its risk factors among diabetic patients in the Eastern Province of Saudi Arabia
    Ahmed Elshebiny, Hassan Alali, Zainab Alamer, Yasmin Alsultan, Hashim Alkhalaf, Abdullah Alkishi, Mohammed Alsuwaylih
    International Journal of Medicine in Developing Countries.2021; : 614.     CrossRef
  • Current trends in epidemiology of cardiovascular disease and cardiovascular risk management in type 2 diabetes
    Jae-Seung Yun, Seung-Hyun Ko
    Metabolism.2021; 123: 154838.     CrossRef
  • Real-world Evaluation of glycemic control and hypoglycemic Events among type 2 Diabetes mellitus study (REEDS): a multicentre, cross-sectional study in Thailand
    Bancha Satirapoj, Thongchai Pratipanawatr, Boonsong Ongphiphadhanakul, Sompongse Suwanwalaikorn, Yupin Benjasuratwong, Wannee Nitiyanant
    BMJ Open.2020; 10(2): e031612.     CrossRef
  • Predictors of Diabetes Self-Care Practice Among Patients with Type 2 Diabetes in Public Hospitals in Northeastern Ethiopia: A Facility-Based Cross-Sectional Study


    Tesfaye Molla Gulentie, Ebrahim Mohammed Yesuf, Taklo Simeneh Yazie, Belayneh Kefale
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 3137.     CrossRef
  • Hypoglycemia in Older Patients
    Byron J. Hoogwerf
    Clinics in Geriatric Medicine.2020; 36(3): 395.     CrossRef
  • Severe hypoglycaemia and absolute risk of cause-specific mortality in individuals with type 2 diabetes: a UK primary care observational study
    Francesco Zaccardi, Suping Ling, Claire Lawson, Melanie J. Davies, Kamlesh Khunti
    Diabetologia.2020; 63(10): 2129.     CrossRef
  • Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4
    Carolina C. Betônico, Silvia Maria O. Titan, Aécio Lira, Tatiana S. Pelaes, Maria Lúcia C. Correa-Giannella, Márcia Nery, Márcia Queiroz
    Clinical Therapeutics.2019; 41(10): 2008.     CrossRef
  • Efficacy and Safety of Degludec Compared to Glargine 300 Units/mL in Insulin-Experienced Patients With Type 2 Diabetes: Trial Protocol Amendment (NCT03078478)
    Athena Philis-Tsimikas, Irene Stratton, Lone Nørgård Troelsen, Britta Anker Bak, Lawrence A. Leiter
    Journal of Diabetes Science and Technology.2019; 13(3): 498.     CrossRef
  • Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes
    Yehuda Handelsman, Christina Chovanes, Terry Dex, Francesco Giorgino, Neil Skolnik, Elisabeth Souhami, William Stager, Elisabeth Niemoeller, Juan Pablo Frias
    Journal of Diabetes and its Complications.2019; 33(3): 236.     CrossRef
  • Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
    Victor Sokolov, Tatiana Yakovleva, Shinya Ueda, Joanna Parkinson, David W. Boulton, Robert C. Penland, Weifeng Tang
    Diabetes, Obesity and Metabolism.2019; 21(4): 829.     CrossRef
  • Effects on clinical outcomes of intensifying triple oral antidiabetic drug (OAD) therapy by initiating insulin versus enhancing OAD therapy in patients with type 2 diabetes: A nationwide population‐based, propensity‐score‐matched cohort study
    Shihchen Kuo, Chun‐Ting Yang, Jin‐Shang Wu, Huang‐Tz Ou
    Diabetes, Obesity and Metabolism.2019; 21(2): 312.     CrossRef
  • Cardiovascular safety and lower severe hypoglycaemia of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: Results from DEVOTE (DEVOTE 7)
    Richard E. Pratley, Scott S. Emerson, Edward Franek, Matthew P. Gilbert, Steven P. Marso, Darren K. McGuire, Thomas R. Pieber, Bernard Zinman, Charlotte T. Hansen, Melissa V. Hansen, Thomas Mark, Alan C. Moses, John B. Buse
    Diabetes, Obesity and Metabolism.2019; 21(7): 1625.     CrossRef
  • Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
    Marile Santamarina, Curt J. Carlson
    BMC Cardiovascular Disorders.2019;[Epub]     CrossRef
  • Effects of a 12-week moderate-intensity exercise training on blood glucose response in patients with type 2 diabetes
    Shang-Lin Chiang, Margaret McLean Heitkemper, Yi-Jen Hung, Wen-Chii Tzeng, Meei-Shyuan Lee, Chia-Huei Lin
    Medicine.2019; 98(36): e16860.     CrossRef
  • Impaired Awareness of Hypoglycaemia in Insulin-treated Type 2 Diabetes Mellitus
    Mohammad J. Alkhatatbeh, Nedaa A. Abdalqader , Mohammad A.Y. Alqudah
    Current Diabetes Reviews.2019; 15(5): 407.     CrossRef
  • Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management
    Stephanie A Amiel, Pablo Aschner, Belinda Childs, Philip E Cryer, Bastiaan E de Galan, Brian M Frier, Linda Gonder-Frederick, Simon R Heller, Timothy Jones, Kamlesh Khunti, Lawrence A Leiter, Yingying Luo, Rory J McCrimmon, Ulrik Pedersen-Bjergaard, Eliza
    The Lancet Diabetes & Endocrinology.2019; 7(5): 385.     CrossRef
  • Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population‐based cohort study
    Kristian B. Filion, Antonios Douros, Laurent Azoulay, Hui Yin, Oriana H. Yu, Samy Suissa
    British Journal of Clinical Pharmacology.2019; 85(10): 2378.     CrossRef
  • Selectivity of beta-blockers, cardiovascular and all-cause mortality in people with hypoglycaemia: An observational study
    F. Zaccardi, L.L. Nystrup Husemoen, B.L. Thorsted, D.R. Webb, S.K. Paul, M.J. Davies, K. Khunti
    Nutrition, Metabolism and Cardiovascular Diseases.2019; 29(5): 481.     CrossRef
  • Cost-effectiveness of a primary care multidisciplinary Risk Assessment and Management Program for patients with diabetes mellitus (RAMP-DM) over lifetime
    Fangfang Jiao, Eric Yuk Fai Wan, Colman Siu Cheung Fung, Anca Ka Chun Chan, Sarah Morag McGhee, Ruby Lai Ping Kwok, Cindy Lo Kuen Lam
    Endocrine.2019; 63(2): 259.     CrossRef
  • Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend
    Ana María Gómez, Diana Cristina Henao, Angelica Imitola, Oscar Mauricio Muñoz, Martín Alonso Rondón Sepúlveda, Laura Kattah, Juan Sebastian Guerrero, Elly Morros, Juan Pablo Llano, Maira García Jaramillo, Fabián León-Vargas
    Endocrinología, Diabetes y Nutrición.2018; 65(8): 451.     CrossRef
  • Recent diabetes-related mortality trends in Romania
    Sorin Ioacara, Elisabeta Sava, Olivia Georgescu, Anca Sirbu, Simona Fica
    Acta Diabetologica.2018; 55(8): 821.     CrossRef
  • Use of sodium-glucose co-transporter-2 inhibitors from clinical trial results to practical application in Russia
    D. A. Lebedev, A. Yu. Babenko
    Medical Council.2018; (16): 100.     CrossRef
  • Severe hypoglycemia is a risk factor for atrial fibrillation in type 2 diabetes mellitus: Nationwide population-based cohort study
    Seung-Hyun Ko, Yong-Moon Park, Jae-Seung Yun, Seon-Ah Cha, Eue-Keun Choi, Kyungdo Han, Eugene Han, Yong-ho Lee, Yu-Bae Ahn
    Journal of Diabetes and its Complications.2018; 32(2): 157.     CrossRef
  • Antioxidant effects of epigallocatechin-3-gallate on the aTC1-6 pancreatic alpha cell line
    Ting Cao, Xiong Zhang, Dan Yang, Yue-Qian Wang, Zheng-Dong Qiao, Jian-Ming Huang, Peng Zhang
    Biochemical and Biophysical Research Communications.2018; 495(1): 693.     CrossRef
  • Hemoglobin glycation index predicts cardiovascular disease in people with type 2 diabetes mellitus: A 10-year longitudinal cohort study
    Mee Kyoung Kim, Jee Sun Jeong, Jae-Seung Yun, Hyuk-Sang Kwon, Ki Hyun Baek, Ki-Ho Song, Yu-Bae Ahn, Seung-Hyun Ko
    Journal of Diabetes and its Complications.2018; 32(10): 906.     CrossRef
  • Day-to-day fasting glycaemic variability in DEVOTE: associations with severe hypoglycaemia and cardiovascular outcomes (DEVOTE 2)
    Bernard Zinman, Steven P. Marso, Neil R. Poulter, Scott S. Emerson, Thomas R. Pieber, Richard E. Pratley, Martin Lange, Kirstine Brown-Frandsen, Alan Moses, Ann Marie Ocampo Francisco, Jesper Barner Lekdorf, Kajsa Kvist, John B. Buse
    Diabetologia.2018; 61(1): 48.     CrossRef
  • Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend
    Ana María Gómez, Diana Cristina Henao, Angelica Imitola, Oscar Mauricio Muñoz, Martín Alonso Rondón Sepúlveda, Laura Kattah, Juan Sebastian Guerrero, Elly Morros, Juan Pablo Llano, Maira García Jaramillo, Fabián León-Vargas
    Endocrinología, Diabetes y Nutrición (English ed.).2018; 65(8): 451.     CrossRef
  • Time- and frequency-domain measures of heart rate variability predict cardiovascular outcome in patients with type 2 diabetes
    Seon-Ah Cha, Yong-Moon Park, Jae-Seung Yun, Seung-Hwan Lee, Yu-Bae Ahn, Sung-Rae Kim, Seung-Hyun Ko
    Diabetes Research and Clinical Practice.2018; 143: 159.     CrossRef
  • Newly diagnosed type 2 diabetes in an ethnic minority population: clinical presentation and comparison to other populations
    Michael Morkos, Bettina Tahsin, Louis Fogg, Leon Fogelfeld
    BMJ Open Diabetes Research & Care.2018; 6(1): e000568.     CrossRef
  • DEVOTE 3: temporal relationships between severe hypoglycaemia, cardiovascular outcomes and mortality
    Thomas R. Pieber, Steven P. Marso, Darren K. McGuire, Bernard Zinman, Neil R. Poulter, Scott S. Emerson, Richard E. Pratley, Vincent Woo, Simon Heller, Martin Lange, Kirstine Brown-Frandsen, Alan Moses, Jesper Barner Lekdorf, Lucine Lehmann, Kajsa Kvist,
    Diabetologia.2018; 61(1): 58.     CrossRef
  • Intervention effects of Compound Houttuyniae Herba to diabetic renal damage based on SOCS-JAK/STAT negative feedback regulation
    Yun Fang, Sai-cong Shao, Hai-ying Wang
    Chinese Herbal Medicines.2018; 10(4): 424.     CrossRef
  • Monotherapy in Patients with Type 2 Diabetes Mellitus
    Sang Youl Rhee, Hyun Jin Kim, Seung-Hyun Ko, Kyu-Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Kyung Mook Choi, Jin Hwa Kim
    Diabetes & Metabolism Journal.2017; 41(5): 349.     CrossRef
  • Monotherapy in patients with type 2 diabetes mellitus
    Sang Youl Rhee, Hyun Jin Kim, Seung-Hyun Ko, Kyu Yeon Hur, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Kyung Mook Choi, Jin Hwa Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 959.     CrossRef
  • Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    The Korean Journal of Internal Medicine.2017; 32(6): 947.     CrossRef
  • Cardiovascular effects of dipeptidyl peptidase-4 inhibitor in diabetic patients with and without established cardiovascular disease: a meta-analysis and systematic review
    Shishi Xu, Xinyue Zhang, Lizhi Tang, Fang Zhang, Nanwei Tong
    Postgraduate Medicine.2017; 129(2): 205.     CrossRef
  • Antihyperglycemic Agent Therapy for Adult Patients with Type 2 Diabetes Mellitus 2017: A Position Statement of the Korean Diabetes Association
    Seung-Hyun Ko, Kyu-Yeon Hur, Sang Youl Rhee, Nan-Hee Kim, Min Kyong Moon, Seok-O Park, Byung-Wan Lee, Hyun Jin Kim, Kyung Mook Choi, Jin Hwa Kim
    Diabetes & Metabolism Journal.2017; 41(5): 337.     CrossRef
  • Effects of propofol on myocardial ischemia-reperfusion injury in rats with type-2 diabetes mellitus
    Ying Wang, Xiuru Qi, Chunliang Wang, Danning Zhao, Hongjie Wang, Jianxin Zhang
    Biomedical Reports.2017; 6(1): 69.     CrossRef
  • Cardiovascular risk assessment in patients with diabetes
    Marcello Casaccia Bertoluci, Viviane Zorzanelli Rocha
    Diabetology & Metabolic Syndrome.2017;[Epub]     CrossRef
  • Pathogenetic features of the combined course of arterial hypertension and diabetes mellitus 2 type
    O.M. Bilovol, L.R. Bobronnikova, O.V. Al-Trawneh
    Shidnoevropejskij zurnal vnutrisnoi ta simejnoi medicini.2017; 2017(1): 4.     CrossRef
  • Risk Factors and Adverse Outcomes of Severe Hypoglycemia in Type 2 Diabetes Mellitus
    Jae-Seung Yun, Seung-Hyun Ko
    Diabetes & Metabolism Journal.2016; 40(6): 423.     CrossRef
  • Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study
    Koutaro Yokote, Yasuo Terauchi, Ichiro Nakamura, Haruko Sugamori
    Expert Opinion on Pharmacotherapy.2016; 17(15): 1995.     CrossRef
  • Hypoglycemia: Culprit or Bystander?
    You-Cheol Hwang
    Diabetes & Metabolism Journal.2016; 40(3): 190.     CrossRef
  • Schwere Hypoglykämien erhöhen die Mortalität
    E. Fritschka
    MMW - Fortschritte der Medizin.2016; 158(S3): 46.     CrossRef

Diabetes Metab J : Diabetes & Metabolism Journal